Systemically expressed soluble Tie2 inhibits intraocular neovascularization

Human Gene Therapy

Volumn 12, Issue 10, 2001, Pages 1311-1321

  Hangai, M ^a   Yuen Sung Moon, ^a   Kitaya, N ^a   Chan, C K ^a   Wu, D Y ^a   Peters, K G ^b   Ryan, S J ^a,c   Hinton, D R ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BETA GALACTOSIDASE; FLUORESCEIN SODIUM; LECTIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRUCH MEMBRANE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HISTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; ISCHEMIA; MALE; MEMBRANE RUPTURE; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VIRUS EXPRESSION;

ADENOVIRIDAE; AGE FACTORS; ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; FLUORESCEIN; GENE THERAPY; ISCHEMIA; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2; RETINAL VESSELS; SIGNAL TRANSDUCTION; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA; MURINAE; RNA VIRUSES;

EID: 0034913943     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750270968     Document Type: Article

References (53)

1. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
2. Vascular endothelial growth factor: 20th-cen-tury mechanisms, 21st-century therapies
3. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
4. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
5. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration
6. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization
7. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation
8. Role of integrins in angiogenesis
9. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration
10. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate
11. Mechanisms of retinal and choroidal neovascularization
12. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning
13. Clinical applications of angiogenic growth factors and their inhibitors
14. Inhibition of angiogenesis
15. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy
16. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization
17. Signaling vascular morphogenesis and maintenance
18. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
19. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: A role of VEGF and possible treatment for SRN in age-related macular degeneration
20. Expression of vascular endothelial growth factor in experimental choroidal neovascularization
21. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders
22. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes
23. Angiopoietin-1 induces sprouting angiogenesis in vitro
24. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
25. VEGF is major stimulator in model of choroidal neovascularization
26. Ocular neovascularization: An epidemiologic review
27. Antiangiogenic gene therapy targeting the endothelium- specific receptor tyrosine kinase Tie2
28. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
29. Angiopoietin- 2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
30. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects
31. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
32. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy
33. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization
34. Ocular neovascularization: Clarifying complex interactions
35. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
36. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid
37. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
38. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
39. Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system
40. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
41. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy
42. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
43. Oxygen-induced retinopathy in the mouse
44. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
45. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
46. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
47. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis
48. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
49. Angiopoietin-1 protects the adult vasculature against plasma leakage
50. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model
51. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase Tie2
52. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues
53. Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats